| 產(chǎn)品名稱 | LS129-3C3-E3-1 [3C3] |
|---|---|
| 商品貨號 | B231959 |
| Organism | Mus musculus (B cell); Mus musculus (lymphoma), mouse (B cell); mouse (lymphoma) |
| Cell Type | hybridoma:lymphoblast B lymphocyte |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain | Strain:? BALB/c (B cell); BALB/c (myeloma) |
| Applications | The antibody binds to the CC chemokine receptor CCR9 (GPR-9-6) and blocks the binding of the thymus-expressed chemokine (TECK) ligand to the receptor. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | Animals were immunized with a peptide consisting of the NH2 terminus of GPR-9-6 having the sequence MADDYGSESTSSMEDYVNFNFTDFYC.
Spleen cells were fused with Sp2/0 myeloma cells. The antibody binds to the CC chemokine receptor CCR9 (GPR-9-6) and blocks the binding of the thymus-expressed chemokine (TECK) ligand to the receptor. |
| Comments | Animals were immunized with a peptide consisting of the NH2 terminus of GPR-9-6 having the sequence MADDYGSESTSSMEDYVNFNFTDFYC.
Spleen cells were fused with Sp2/0 myeloma cells. The antibody binds to the CC chemokine receptor CCR9 (GPR-9-6) and blocks the binding of the thymus-expressed chemokine (TECK) ligand to the receptor. |
| Complete Growth Medium | Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose and supplemented with 50 ng/ml mouse recombinant Interleukin-6 (IL-6) and 10% fetal bovine serum
|
| Subculturing | Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 3 X 10(4) viable cells/ml. Interval: Maintain cultures at a cell concentration between 3 X 10(4) and 1 X 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype | IgG2b |
| Population Doubling Time | 18 hours |
| Name of Depositor | LeukoSite, Inc. |
| U.S. Patent Number | |
| References | Zabel BA, et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis.. J. Exp. Med. 190: 1241-1256, 1999. PubMed: 10544196 Andrew DP, et al. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function. US Patent 6,329,159 dated Dec 11 2001 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
